Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose rituximab guided by B-cell count for nephrotic syndrome
ChiCTR1900026382Phase 4Completed
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Nov 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rituximab in nephrosis, sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: Remission rate. Started Nov 2019; status: completed.
02
Drugs
rituximab
03
Conditions
nephrosis
Beyond the preview
Go deeper on ChiCTR1900026382.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026382.